Navigation Links
Osteotech Engages BioHorizons as Exclusive Distributor to International Dental Market
Date:4/30/2008

EATONTOWN, N.J., April 30 /PRNewswire-FirstCall/ -- Osteotech, Inc. (Nasdaq: OSTE), a leader in the emerging field of biologic solutions for regenerative medicine, announced today that it has signed an exclusive distribution agreement with BioHorizons, Inc., effective as of April 1, 2008, under which BioHorizons will market Osteotech's bone regeneration products to the dental market in 29 countries in Europe, the Middle East, Latin America and Asia. Osteotech and BioHorizons previously entered into an agreement for BioHorizons to distribute Osteotech's products to the United States dental market in 2000.

Sam Owusu-Akyaw, Osteotech's President and Chief Executive Officer, commented, "Our domestic relationship with BioHorizons has been very successful and we are pleased to be able to expand this relationship overseas. We believe our bone regeneration products are the perfect solution for the new bone grafting procedures being developed to replace missing or extracted teeth with dental implants or as support for dentures, crowns and bridges."

BioHorizons is a leading oral reconstructive device company at the forefront of digital dentistry. The company has a broad product offering, including surgical planning software, regenerative products, dental implants, CAD/CAM and traditional dental restorations. BioHorizons has a direct sales force in the U.S., Canada, Germany, Spain, United Kingdom, Australia, Mexico, and Chile. Products are distributed in the rest of the world via a network of independent distributors.

Osteotech, Inc., headquartered in Eatontown, New Jersey, is a global leader in providing OsteoBiologic solutions for regenerative medicine to support surgeons and their patients in the repair of the musculoskeletal system through the development of innovative therapy-driven products that alleviate pain, promote biologic healing and restore function. For further information regarding Osteotech or this press release, please go to Osteotech's website at http://www.osteotech.com.

Certain statements made throughout this press release that are not historical facts contain forward-looking statements (as such are defined in the Private Securities Litigation Reform Act of 1995) regarding the Company's future plans, objectives and expected performance. Any such forward-looking statements are based on assumptions that the Company believes are reasonable, but are subject to a wide range of risks and uncertainties and, therefore, there can be no assurance that actual results may not differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, the Company's ability to develop and introduce new products, differences in anticipated and actual product and service introduction dates, the ultimate success of those products in the marketplace, the continued acceptance and growth of current products and services, the impact of competitive products and services, the availability of sufficient quantities of suitable donated tissue and the success of cost control and margin improvement efforts. Certain of these factors are detailed from time to time in the Company's periodic reports filed with the Securities and Exchange Commission. All information in this press release is as of April 30, 2008 and the Company does not intend to update this information.


'/>"/>
SOURCE Osteotech, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Osteotech Signs Agreement To Distribute Harvest Technologies BMAC(TM) System
2. Osteotech Reports 2007 Third Quarter Financial Results; Core Segment Revenue Increased 28%; Gross Margin Improved to 55%; Diluted Earnings Per Share of $.09
3. Osteotech Announces Third Quarter Earnings Release and Conference Call Schedule
4. Osteotech Completes Tissue Supply Agreement With LifeNet Health
5. Osteotech to Present at First Albany Capitals Regenerative Technologies Conference in New York
6. ISTA Pharmaceuticals Engages Cowen as Financial Advisor
7. Cardiome Announces Positive Interim Phase 2b Results for Oral Vernakalant and Engages Merrill Lynch as Strategic Advisor
8. Availity Engages Prematics to Deploy Electronic Prescribing Solution
9. Availity Engages Prematics to Deploy Electronic Prescribing
10. MiddleBrook Pharmaceuticals Engages Morgan Stanley in Its Strategic Process
11. Roche Engages in Four Additional AIDS Technology Transfers to Strengthen Local Manufacturing in Worlds Poorest Countries
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2017)... Alexandria, VA (PRWEB) , ... June 23, 2017 ... ... short of what is needed and will ultimately do significant harm to people ... care to everyone. , "While it leaves in place the Affordable Care ...
(Date:6/23/2017)... ... June 23, 2017 , ... Yesterday, U.S. Senate Republicans ... to repeal and replace the Affordable Care Act (ACA). Like the bill narrowly ... to Medicaid, a public health insurance program for low-income children, pregnant women, parents ...
(Date:6/23/2017)... ... ... The Military Officers Association of America (MOAA) announced its support for the ... Col. Thomas G. Bowman. , Bowman currently serves as the staff director for the ... issues and challenges veterans face with the VA. Following a 30-year career of service ...
(Date:6/23/2017)... ... June 23, 2017 , ... Military Connection friend and ... to the JFK Virgin Atlantic lounge. , Bensko is no stranger to the ... ago, Bensko dedicated her life to supporting our wounded veterans. A world-class photographer, her ...
(Date:6/23/2017)... ... June 23, 2017 , ... Goodcents Deli Fresh Subs today announced the ... at 4210 SW 21st St. Topeka, Kan. 66604 (near 21st and Gage). It is ... who owns three other locations in the Topeka and Bonner Springs, Kan. area. ...
Breaking Medicine News(10 mins):
(Date:6/3/2017)... , June 3, 2017  Eli Lilly and ... that results from the Phase 3 MONARCH 2 ... & 6 inhibitor, in combination with fulvestrant, significantly ... fulvestrant alone in women with hormone-receptor-positive (HR+), human ... cancer who have relapsed or progressed after endocrine ...
(Date:5/30/2017)... , May 30, 2017 Hill-Rom Holdings, Inc. ... Annual Global Healthcare Conference on Tuesday, June 13, 2017, ... John Greisch , Hill-Rom,s president and chief executive officer, is ... The live audio webcast can be accessed at http://ir.hill-rom.com/events.cfm ... conclusion of the live event through September 13, 2017. ...
(Date:5/26/2017)... 25, 2017  In response to the opioid epidemic ... Relief is working with Pfizer to make up to ... cost to community health centers, free and charitable clinics, ... "Pfizer has a long-standing commitment to improving ... patient safety through educational activities," said Caroline Roan ...
Breaking Medicine Technology: